GHP Q1 2022

GHP / Q1 2022 25 Dedicated Developments device in multiple international markets, Medovate now has agreements in place to make the technology available in 60+ countries over the next few years. The company also has a number of exciting additional innovations in the pipeline, including their novel HME safety device HUMIDICARE®, a novel heat and moisture exchanger (HME) which has a safety engineered warning system to promptly visually alert staff to a dual humidification error in a ventilation circuit, helping prevent potential harm to patients. In the field of critical care, the company has developed Glucosave®, a patient safety solution designed to help prevent incidences of unnecessary administration of insulin following blood sampling where a glucose containing flush solution has been inadvertently connected, something which can have serious consequences for patients. With the wind firmly in their sails, Medovate is also actively pursuing further regulatory approvals and distribution agreements for other key markets across Asia-Pacific, Canada and South Africa. With further regulatory approvals for the promising technologies in the Medovate portfolio imminently anticipated, and additional technologies approaching clinical trials and market launch, this is just the beginning for this fast-growing company, which has grown from an initial team of 2 to a team of 16, including a consultant based in the US – the home of its first product launch. Medovate now continues to work with distributor partners who are global leaders in their field to bring its innovations to market, such as Vygon in markets including Europe and the UK; and Mercury Medical, through which it is working to distribute SAFIRA® across the whole of the United States. The company also has a co-promotional partnership agreement with Konica Minolta Healthcare Americas Inc. – a world-class provider and market leader in medical diagnostic imaging – to promote best practice in ultrasound guided regional anaesthesia across the US. The partnership was formed to highlight the provision of Ultrasound Guided Regional Anaesthesia’ and how the ground-breaking SAFIRA® can be used in conjunction with Konica Minolta Healthcare Americas’ Inc. range of pioneering ultrasound solutions. Today Medovate continues to work with partners to uncover further NHS innovations to add to its portfolio, keep the positive cycle of developing NHS innovation going and realising its potential to help support further NHS innovation; while also raising awareness of the amazing innovations generated by the NHS which can benefit clinicians and patients beyond the UK. Through its partners and co-promotional partners, the company continues to work towards its vision to promote patient safety through healthcare innovations arising from the UK’s world leading institution – which, as an additional benefit, remains a key stakeholder for the organisation. The company operates a unique model ensuring the Trusts where its new device ideas originate receive a share of the profits from successful commercialisation, thus helping it to feed into the healthcare innovation cycle in an exceptional way. Company: Medovate Contact: Chris Rogers Website: medovate.co.uk

RkJQdWJsaXNoZXIy MTQxNTg3MQ==